A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

The idea for Splay, a unique device perfect for a mobile workforce, was born on the Rice University campus. Images courtesy

Houston startup founders take one-of-a-kind projection device into manufacturing phase

splay saves the day

A Houston company born out of Rice University has crowdfunded its way into the manufacturing phase of its startup journey.

Arovia, founded by Alex Wesley and George Zhu, has a product that solves some major obstacles people on the go face as they work — or entertain — from home, a hotel, coffee shop, etc. Splay is a unique collapsable, portable device that doubles as both a display and projector.

The founders first launched their product in 2016 and raised over $700,000 from backers on their crowdfunding campaign. After raising investment funding, including an investment from the Texas Halo Fund, Wesley and Zhu recently returned to their crowdfunding roots and ran a 30-day pre-order campaign on Kickstarter during which they sold over $300,000 worth of product.

“We couldn't have made Splay without the Houston Startup Community," Wesley says.

Wesley was an MBA student when he met Zhu, who was working towards a B.S. in Mechanical Engineering, after posting a job description in search of a co-founder, a requirement of the Owlspark program.

“Owlspark accepted the business idea, with the stipulation that I needed to find a co-founder,” says Wesley. “I sent out a job description, and a big part of the application process was to provide ideas for making this crazy idea work. I sent the job description at around 9 pm and received an email from George at around 1 am with an extremely detailed proposal. That was the start; and since then, we’ve basically been like brothers — I’ve even lived with him and his parents in China.”

Wesley credits Owlspark as an important part of their formation, beyond the impetus for their partnership.

“It was a great experience for us. The focus on customer interviews is something that is very easy to avoid, but it’s extremely important. You don’t have a product if nobody wants to buy it — you don’t have a company without customers," Wesley says. "During our time at Owlspark, we did over 100 customer interviews, which gave a lot of insight into the viability of the idea and who it would be useful for. We still utilize many of those insights today.”

But Owlspark wasn’t the only accelerator program that Wesley and Zhu joined. They also participated in Hax, a top hardware-focused accelerator, and Luminate, a top optics-focused accelerator. They also competed in the Rice Business Plan Competition, which Wesley says helped them refine their pitch which ultimately secured their funding.

“We pitched at angel groups including the Houston Angel Network and their fund The Halo Fund, Keiretsu Forum and their fund Keiretsu Capital, Rochester Angel Network, and the GOOSE Society. We also won the Texas A&M New Venture Competition,” says Wesley.

With this financial backing, Arovia received the necessary support for the R&D phase for Splay, taking the product into its manufacturing process and pre-sale campaign.

“Yes, it went very well,” shares Wesley, adding that they are still looking for support on the Indiegogo campaign. “Now we are focusing on pre-selling in other markets, like Japan."

Splay can be used as a portable screen, or the projector can be removed to be used on its own. Photo via Splay

This week's roundup of Houston innovators includes John Chappell of BlockApps, Kyra Doolan of Texas HALO Fund, and Shaun Noorian of Empower Pharmacy. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from venture capital to pharmacy — recently making headlines in Houston innovation.

John Chappell, director of energy business development at BlockApps

Siloed data, lack of consistency, and confusing regulations are all challenges blockchain can address, says this expert. Photo courtesy

Houston has all the potential to lead the energy transition — it just needs to make sure it has all the right ingredients. According to John Chappell, a key ingredient is blockchain. He explains in a guest article for InnovationMap.

"Houston has earned its title as the Energy Transition Capital of the world, and now it has an opportunity to be a global leader of technology innovation when it comes to carbon emissions reporting," Chappell writes. "The oil and gas industry has set ambitious goals to reduce its carbon footprint, but the need for trustworthy emissions data to demonstrate progress is growing more apparent — and blockchain may hold the keys to enhanced transparency." Click here to read more.

Kyra Doolan, managing director at Texas HALO Fund

Kyra Doolan joins the Houston Innovators Podcast to discuss the huge opportunities for innovation within femtech. Photo via LinkedIn

When venture capitalist and angel investing expert Kyra Doolan started navigating her own fertility journey, her eyes were opened to a huge market opportunity across femtech. As managing director at Houston-based Texas HALO Fund, she took these opportunities to her team of investors.

"A lot of the issues that face women, are things that are not talked about," she says on this week's episode of the Houston Innovators Podcast, referencing things like miscarriage, injury during childbirth, etc. "For a lot time, women just sat back if they had these issues, and they kept it to themselves, so those problems weren't being addressed."

Doolan says she and other women aren't taught how to manage their own fertility journey, but it doesn't have to be that way. Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy

Empower Pharmacy has opened its new 86,000-square-foot facility features innovative technology for purifying water, automation, and more. Photo courtesy of Empower Pharmacy

Houston-based Empower Pharmacy has celebrated the grand opening of its new $55 million, 86,000-square-foot facility that includes extensive automation, a top-of-the line cleanroom, and equipment that generates purified water, clean steam, and clean compressed air. The space also features a warehouse capable of storing at least nine months of raw pharmaceutical ingredients to minimize supply chain problems.

"This innovative facility, combined with our more than 500 dedicated employees, enables us to increase our operational capacity, allowing us to prepare thousands of custom prescriptions each day for millions of patients across the country," Shaun Noorian, founder and CEO of Empower Pharmacy, says in a news release. "We are setting a new standard for compounded medicine, striving to achieve a superior pharmaceutical experience, from order placement to delivery."

The new Empower Pharmacy facility, at 7601 N. Sam Houston Parkway W., opened earlier this month. Click here to read more.

Kyra Doolan joins the Houston Innovators Podcast to discuss the huge opportunities for innovation within femtech. Photo via LinkedIn

Houston investor shares why she's focused on funding the future of femtech

HOUSTON INNOVATORS PODCAST EPISODE 98

Successful investors find gaps in the marketplace and direct funds into startups and technologies resolving those gaps. For Kyra Doolan, managing director at Houston-based Texas HALO Fund, femtech represents a huge opportunity for innovation.

"A lot of the issues that face women, are things that are not talked about," she says on this week's episode of the Houston Innovators Podcast, referencing things like miscarriage, injury during childbirth, etc. "For a lot time, women just sat back if they had these issues, and they kept it to themselves, so those problems weren't being addressed."

While Texas HALO Fund has invested in femtech since its first fund in 2012, Doolan shares on the show how she personally saw an investment opportunity with kegg, a fertility tracking device. Doolan says she and other women aren't taught how to manage their own fertility journey, but it doesn't have to be that way.

"I was at a stage in my life where my eyes were open to the gaps that are out there and the conversations that weren't being had," she says. "In looking into Kegg, it showed me what the market was and how many gapes there were in the market just around fertility."

Texas HALO Fund has a few femtech companies in its portfolio now, and the most recent addition is Houston-based Work & Mother, a company that builds out fully-equipped nursing accommodations in office buildings.

Despite it's growing femtech portfolio, the fund is industry agnostic, though, Doolan says, about a third of the companies Texas HALO Fund invests in reside in the health tech space. What makes HALO different is its focus on early-stage startups.

"We like to get in early," Doolan says. "We're, what you would historically consider 'pre-VC,' but now that's getting a little bit blurred. ... We're some of the earlier capital that's invested, and we continue to make investment as the companies continue to subsequent rounds."

Doolan shares more on her passion for femtech, as well as her advice for founders looking for funding and potential female investors looking to get into investing on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Unlike past awards programs hosted by Ignite Healthcare Network, the Ignite Madness winners accepted their awards via video call. Photo courtesy of Ignite

Houston female-focused health tech pitch competition names big winners

winner, winner

From the comfort of their own homes, several female entrepreneurs accepted investment and pitch prizes at the finals of an inaugural awards program created by a Houston-based, woman-focused health organization.

Ahead of the Ignite Madness finals on Thursday, October 29, Houston-based Ignite Healthcare Network named nine finalists that then pitched for three investment prizes. The finalists included:

  • Eden Prairie, Minnesota-based Abilitech Medical — medical device company that creates assistive devices to aid those with upper-limb neuromuscular conditions or injuries.
  • New Orleans, Louisiana-based Chosen Diagnostics — a biotech company focusing on custom treatment. First, Chosen is focused on creating two novel biomarker diagnostic kits — one for gastrointestinal disease in premature infants.
  • San Francisco, California-based Ejenta — which uses NASA tech and artificial intelligence to enhance connected care.
  • Highland, Maryland-based Emergency Medical Innovation — a company focused on emergency medicine like Bleed Freeze, a novel device for more efficiently treating nosebleeds.
  • Columbia, Missouri-based Healium — an app to quickly reduce burnout, self-manage anxiety, and stress.
  • Farmington, Connecticut-based Nest Collaborative — digital lactation solutions and support.
  • Palo Alto, California-based Nyquist Data — a smart search engine to enable medical device companies to get FDA approvals faster.
  • New Orleans-Louisiana based Obatala Sciences — a biotech startup working with research institutions across the globe to advance tissue engineering and regenerative medicine.
  • Perth, Australia-based OncoRes — a company that's developing a technology to provide surgeons with real-time assessment of tissue microstructure.
The inaugural event that mixed health care and basketball — two vastly different industries with strong connections to women — attracted support from partners and sponsors, such as Intel, Accenture, Morgan Lewis, Houston Methodist, Johnson & Johnson Innovation, and more, according to Ayse McCracken, founder and board chair of Ignite.

"Our partners and sponsors are an integral part of our organization" says McCracken. "Without each and every one of them, the networks, resources, and commitment to advancing women leaders, we would not have grown so rapidly in just four years and our IGNITE Madness event would not enjoy this vibrant ecosystem that now surrounds female entrepreneurs."

First up in selecting their winner for their investment was Texas Halo Fund. Chosen Diagnostics took home the $50,000 investment.

"While we were impressed by everyone who pitched tonight, one company stood out to us," says Kyra Doolan, managing partner. "[Chosen Diagnostics] exemplifies what we are looking for: an innovative solution, a strong CEO, and a real addressable market."

The second monetary award was presented by Tom Luby, director of TMC Innovation. The award was an $100,000 investment from the TMC Venture Fund, as well as admission to TMCx. The recipient of the investment was OncoRes.

"We are absolutely blown away," says Katharine Giles, founder of Onco. "We've already got a great link to Texas and looking forward to more."

The largest monetary award that was on the table was presented by Wavemaker Three-Sixty Health, a leading Southern-California based, early stage venture capital firm, for $150,000. However, at the time of the announcement, Managing Partner Jay Goss decided to award four startups an undisclosed amount of investment. Goss says he and his team will meet with each company to establish an investment.
The companies that were recognized by Wavemaker were: Healium, Ejenta, Emergency Medical Innovation, and Nest Collaborative.
Lastly, Ignite itself had $27,500 cash awards to give out to the pitch competition winners. The funds will be distributed between the winners. OncoRes took first place, Abilitech came in second place, and Obatala Sciences took third place.
From a Houston startup exit to the growth of a Rice University startup, here's the short stories of Houston innovation news you may have missed. Pexels

Houston energy company exits, 3 recent investments from local fund, and more innovation news

Short stories

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, Texas Halo Fund makes three new investments, a Houston energy company exits, a growing Rice University startup gets grants, and more.

Octopus Energy acquires Houston-founded Evolve Energy

The $5 million deal means a new focus on Texas for the new parent company. Photo via evolvemyenergy.com

London-based renewable energy company Octopus Energy announced that it's acquired Houston-founded Evolve Energy in a $5 million deal, which represents Octopus's $100 million expansion into the United States market.

Octopus, which reached Unicorn status with a $1 billion valuation in April, will start its expansion in Texas, according to a news release, operating under the new name Octopus Energy US. Evolve Energy, which was founded in 2018 by Michael Lee, is a Texas-based Capital Factory portfolio company and finished first place in the 2019 EarthX startup competition. The company also has a Silicon Valley office, in addition to its local operation in Houston's Galleria area.

"Octopus Energy is inspirational in growing a customer base of over 1 million households in just four years. It has done so while also achieving customer satisfaction scores similar to Netflix and Amazon. It matches our aspiration for innovation and we're thrilled to be part of the Octopus family," says Lee in the release. "The US energy market is rapidly moving towards ultra-low cost renewable energy and is prime for a true digital transformation."

Texas Halo Fund makes three new investments

Texas Money

Here are the three latest investments from Texas Halo Fund. Getty Images

Houston-based Texas Halo Fund has made three recent investments in August and September.

  • Nexus AI, based in Chicago, the workforce management tech company uses artificial intelligence and organizational behavioral science to predict the best teams or individuals for a project on the startup's cloud-based platform.
  • Rellevate is a Connecticut-based digital fintech company that optimizes employer-based digital account and financial services.
  • MFB Fertility, a Colorado company, has created game-changing at-home test stripts for assaying the hormone progesterone branded as Proov.

Rice University program seeking data projects

The Rice D2K Lab wants to help startups and small businesses solve business concerns with data science. Photo courtesy of Rice

Adata-focused lab at Rice University is seeking data challenges for its group of next generation of data scientists to solve. The Rice D2K Lab is looking for sponsors for its Rice D2K Capstone project in Spring 2021. Rice's D2K Capstone program forms interdisciplinary teams of advanced undergraduate and graduate students to solve pressing real-world data science challenges. The program is accepting project proposals for the Spring 2021 semester through Monday, October 19.

Click here to learn more about the program, and click here to get involved.

California startup joins Chevron's Catalyst Program

CTV has a new startup in its Catalyst Program. Photo via Getty Images

Houston-based Chevron Technology Ventures announced that Oakland, California-based Brimstone Energy Inc. has joined CTV's Catalyst Program to continue its development of its decarbonization platform, which focuses on the generation of low-emissions hydrogen, as well as various commodity products, according to a release.

"Brimstone Energy is excited to be supported by Chevron, a multi-national industrial company," says Cody Finke, Ph.D., co-founder and CEO of Brimstone Energy, in the release. "It is good to see Chevron continue to back companies with decarbonization in their mission."

Rice University-born startup racks up $12.5 million in grants

OpenStax is growing its access to free online textbooks. Image via openstax.org

Rice University's OpenStax is able to greatly expand its library of free online textbooks thanks to new grants totaling $12.5 million. The funds derive from Bill & Melinda Gates Foundation, the William and Flora Hewlett Foundation, the Charles Koch Foundation and the Stand Together community, according to a press release from Rice.

The new funds will more than double OpenStax's files from 42 books to 90. Already, the platform has saved 14 million students around the world more than $1 billion.

"Nine years ago, we dreamed about solving the textbook affordability and access crisis for students," says Richard Baraniuk, the Victor E. Cameron Professor of Electrical and Computer Engineering at Rice and founder and director of OpenStax, in the release. "Now, with this tremendous investment in open education, we will be able to not only accelerate educational access for tens of millions of students but also drive innovation in high-quality digital learning, which has become commonplace due to COVID-19."

OpenStax is planning to raise $30 million for continued library expansion as it aims to lower the barrier to higher education.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.